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Background: Metabolic syndrome is associated with an increased risk of cardiovascular and hepatic complications.
Oxidative stress in metabolic tissues has emerged as a universal feature of metabolic syndrome and its co-morbidities.
We aimed to develop a rapidly and easily induced model of metabolic syndrome in rats to evaluate its impact on
plasma and tissue oxidative stress.
Materials and methods: Metabolic syndrome was induced in rats using a high-fat diet (HFD), and these rats were
compared to rats fed a normal diet (ND) for 2 months. Metabolic control was determined by measuring body weight,
blood glucose, triglycerides, lipid peroxidation and protein carbonylation in plasma. Insulinemia was evaluated through
the measure of C-peptide. Histological analysis was performed on the pancreas, liver and blood vessels.
Results: After 2 months, the HFD induced an increase in body weight, insulin and triglycerides. Liver steatosis was also
observed in the HFD group, which was associated with an increase in glycogen storage. In the pancreas, the HFD
induced islet hyperplasia. Tissue oxidative stress was also increased in the liver, pancreas and blood vessels, but plasma
oxidative stress remained unchanged.
Conclusion: This paper reports the development of a fast and easy model of rat metabolic syndrome associated with
tissue oxidative stress. This model may be a good tool for the biological validation of drugs or antioxidants to limit or
prevent the complications of metabolic syndrome.
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The consumption of diets high in energy (protein, fat and
carbohydrates) has become a habit in modern societies
despite the reduction in daily energetic needs from 3000
to 2200 kcal [1]. These preferences for high-calorie or
high-fat diets (HFDs) lead to an obesogenic environment
for humans, increasing the risk of developing diseases as-
sociated with metabolic disorders such as obesity and
metabolic syndrome (MS). MS has become a public health
problem throughout the world and is defined by a com-
bination of several metabolic abnormalities: impaired
glucose tolerance or insulin resistance, impaired blood
pressure, dyslipidemia (increase in triglycerides and high-
density lipoprotein cholesterol), cardiovascular alterations* Correspondence: s.sigrist@ceed-diabete.org
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unless otherwise stated.and central obesity [2,3]. These metabolic disorders have
been identified as risk factors for the development of se-
vere complications. In obese patients, ectopic storage of
fat occurs in particular organs and tissues that are not
normally involved in fat storage, such as cardiovascular
tissues including blood vessels [4]. Moreover, fat-engorged
adipocytes and fat-laden myocytes are resistant to the sig-
nalling effects of insulin, leading to the storage of lipids
and triglycerides in several tissues, including the pancreas
and liver [5]. The presence of saturated fat in the liver in
turn causes insulin resistance in this organ [6,7], leading
to NAFLDs (non-alcoholic fatty liver diseases), particularly
steatosis [8]. Other metabolic alterations may also be
added to the list of known and identified factors leading to
MS, with oxidative stress (OS) as one candidate factor [9].
Close links exist between MS and OS [10-12] due to an
imbalance between pro-oxidant and anti-oxidant speciesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Composition of ND and HFD
A04 (ND) WESTERN RD (HFD)
Crude fat (%) 3.1 21.4
Crude protein (%) 16.1 17.5
Crude fibre (%) 3.9 3.5
Ash (%) 5.1 4.1
Carbohydrate (%) 59.9 50
Moisture (%) 11.9 3.5
Atwater fuel energy 2.8 kcal/g 4.6 kcal/g
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metabolic syndrome exhibit damage due to OS [14]. Insu-
lin resistance and inflammation increase reactive oxygen
species (ROS) production and OS [15] through superoxide
anion production and the decreased levels of antioxidative
enzymes such as superoxide dismutase and glutathione
peroxidase [16]. This leads to end products of lipid peroxi-
dation such as malondialdehyde (MDA) and carbonylated
proteins [17] in the plasma and to the accumulation of
ROS in blood vessels [18]. Moreover, the accumulation of
insulin in MS stimulates lipogenesis and further hepatic
glycogen synthesis [19,20].
Faced with the widespread morbidity induced by MS,
scientists are trying to understand the impact of environ-
mental factors on humans using in vivo models. Many
animal models of MS have been developed, including
spontaneous transgenic models and diet-induced models.
The most common spontaneous or transgenic MS models
are i) ob/ob mice (autosomal recessive disease) [21,22];
ii) obese “yellow mice” (autosomal dominant disease)
[23]; iii) NZO (New Zealand Obese) obese mice (poly-
genic disease) [24], and iv) obese Zucker rats [25]. Dietary
models combining high-calorie diets with reductions in
physical activity are easier and cheaper and reflect the nat-
ural history of metabolic syndrome. For example, in the
spiny mouse (Acomys cahirinus), a rich sucrose diet in-
duces glucose intolerance and hyperinsulinemia without
hyperglycemia or obesity, while a high-lipid diet induces
obesity and hyperglycemia [26]. The sand rat (Psamm-
omys obesus) develops obesity and hyperinsulinism associ-
ated with glucose intolerance after three months on a
high-calorie diet. Moreover, after six months, diet can in-
duce insulin-dependence [27]. HFD is well-known to in-
duce some metabolic disorders, and the consequences of
HFD are completely dependent on the composition and
duration of the diet [28,29]. Therefore, these data suggest
that it is possible to develop a model of MS by changing
the composition of the diet. However, it is important to
take the age of the rats in these models into account. The
age of Wistar rats appears to be related to the develop-
ment of metabolic syndrome [3]. Few studies have charac-
terised the metabolic alterations and their consequences
during a short-term diet. Therefore, the dual effects of age
and the duration of the diet could create a bias in these
models.
The aim of this study was to develop a rapid and easy
model of MS and to characterise the metabolic and tis-
sue alterations in that model by subtracting age-related
effects. MS was induced by feeding young and healthy
Wistar rats a HFD containing high levels of lipids. The
animals were then followed for two months to under-
stand the impact of HFD over a short period on the ap-
pearance of MS and its consequences for metabolic
parameters and tissue alterations.Materials and methods
Animals
This study was performed in accordance with the “Guide
for the Care and Use of Laboratory Animals” published
by the US National Institutes of Health (NIH publication
No. 85–23, revised 1996). Every effort was made to min-
imise animal suffering and to reduce the numbers of ani-
mals used. The laboratory has been licensed by the
Department of Veterinary Service (license N° B67-482-
28). The study protocol has been approved through the
license of S. Sigrist (N°67-318).
Male Wistar rats (DEPRE, Saint Doulchard, France)
6 weeks of age were housed in a climate-controlled room
(22 ± 2°C and 60% relative humidity) with a 12 h light/
dark cycle. The rats had ad libitum access to water and
food.
The animals were randomly divided into two equal
groups. The ND group (Normal Diet, n = 6) received the
standard diet (A04, SAFE, Augy, France) with an Atwater
fuel energy of 2.8 kcal/g (Table 1). The HFD group (High-
Fat Diet, n = 10) received the WESTERN RD diet (SDS,
Special Diets Services, Saint Gratien, France) for 2 months,
which has an Atwater fuel energy of 4.6 kcal/g (Table 1).
Metabolic follow-up
All rats were weighed once a week throughout the study
period. Before sacrifice, the rats were fasted overnight, and
rat tail blood samples were collected into Microtainer™
tubes containing lithium heparin (Becton Dickinson,
Franklin Lakes, NJ, USA) during fasting and 30 minutes
after re-feeding. These samples were then stored at −80°C.
Glycemia was measured using the glucose RTU® kit
(Biomérieux, Craponne, France) and expressed in g/L.
The measure of C-peptide was preferred rather than
the measure of insulin to evaluate insulinemia using a
rat C-peptide ELISA kit (Mercodia, Uppsala, Sweden)
and expressed in pmol/L.
Glucose Tolerance Test was performed after an over-
night fast. A 2 g/kg glucose 20% solution was injected
intraperitoneally (IpGTT). Plasma glucose concentration
was evaluated using a glucometer at baseline and 15, 30,
45, 60, 90, and 120 minutes after the glucose load
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Areas under the curve (AUC) were determined to com-
pare groups.
Insulin resistance was evaluated by calculating the
homeostasis model assessment (HOMA2): HOMA2 was
calculated from fasting plasma glucose and fasting serum
C-peptide using the HOMA2 model calculator (http://
www.dtu.ox.ac.uk/homa).Animal sacrifice and collection of the biological material
By the end of the experimental period, all of the rats were
sacrificed. After anaesthesia induced by a mixture of xyla-
zine (Rompun® 2%, Bayer, Puteaux, France) and ketamine
(Imalgène® 1000, Merial, Lyon, France) at a dose of
100 μL/100 g, blood was drawn from the abdominal
aorta into tubes containing EDTA. Plasma samples
were then stored at −80°C. A piece of fresh liver was
weighed and placed in a tube containing sodium acetate
buffer for glycogen determination.
Additional liver and pancreas samples were either
immersed in 4% paraformaldehyde for subsequent paraf-
fin inclusion or embedded in Tissue-Tek® OCT (Electron
Microscopy Sciences, Hatfield, PA, USA) and directly
frozen in liquid nitrogen and stored at −80°C. A piece of
the mesenteric artery was also obtained and embedded
in OCT.Lipid peroxidation
The lipid peroxidation protocol was adapted from the
AMDCC protocol (Animal Models of Diabetic Complica-
tions Consortium). Briefly, 100 μL of plasma was mixed
with 200 μL of 10% trichloroacetic acid (TCA, Fisher Sci-
entific), cooled on ice for 15 minutes, and then centrifuged
at 2200 × g for 15 minutes at 4°C. The supernatants were
then mixed with 200 μL of TBA, 0.67% (Sigma) and
heated in a dry bath at 95°C for 1 hour. Then, 150 μL of
each solution was transferred into a 96-well plate, and the
absorbance was measured at 550 nm. Lipid peroxidation
(μmol/L) was reported with respect to the total amount of
protein in the sample as measured by the Bradford
method [30].Protein carbonylation
Protein carbonylation was determined by the OxiSelect™
assay (Cell Biolabs, Inc., San Diego, CA, USA). This proto-
col was performed according to the manufacturer’s in-
structions, with plasma samples prepared at a final
concentration of 10 mg/mL of total protein. The quan-
tity of carbonylated proteins was measured by spectro-
photometry at 450 nm (iMark, Bio-Rad) and expressed
as nmol/mg of total protein, as determined by the Bradford
assay [30].Triglycerides content
Triglycerides were determined using the Triglycerides
Quantification Kit (BioVision Research Products, Mountain
View, CA, USA) according to the manufacturer’s instruc-
tions. Samples were measured at 550 nm and concentra-
tions were expressed in mmol/L.
Total cholesterol content
Enzymatic determination of total cholesterol was per-
formed using the Cholesterol RTU™ (Biomérieux,
Marcy-l’Etoile, France) according to the manufacturer’s in-
structions. Samples were measured at 550 nm and con-
centrations were expressed in mmol/L.
Hepatic glycogen content
Fresh liver tissue (100 mg) was mixed with a high-
speed homogeniser (Polytron PT MR2100, Kinematica
AG, Luzern, Switzerland) in a sodium acetate buffer
(0.2 M, pH 4.5). An aliquot of homogenate was mixed
with amyloglucosidase (AMGD, Roche Diagnostic) and
incubated at 55°C for 90 min to degrade the glycogen
into glucose residuals. An aliquot without AMGD was
used as a free glucose control. Each aliquot was centri-
fuged (10 min, 4000 × g, 4°C), and the supernatants were
retained for glucose determination. The samples (10 μL)
or reference samples of glucose (0–1 g/L) were incubated
with a glucose detection reagent (ortho-dianisidine + glu-
cose oxidase/peroxidase reagent) at room temperature for
10 min. The amount of glucose was determined by meas-
uring the absorbance at 450 nm. Samples were analysed in
duplicate and the results were determined as μg glycogen
per μg used liver (adapted from [31]).
Histology of liver and pancreas tissue
Paraformaldehyde-fixed liver and pancreas specimens
were embedded in paraffin blocks and cut into 4 μm
thick sections. The sections were then stained with
Masson trichrome (MT) according to standard proce-
dures. The islet surface distribution was determined in
the pancreas. At least three sections were examined per
animal. The islet surface area was measured using
Nikon NIS Elements Br software (Nikon, Tokyo, Japan),
and the distributions were reported using box and
whiskers plots with median, first and third quartile and
extreme values. In the liver, the degree of steatosis was
defined on sections according to Kleiner et al. [32],
with a maximum score of 3. No accumulation of lipids
occurs in the pancreas.
Study of tissue oxidative stress
The oxidative fluorescent dye dihydroethidine (DHE,
Sigma-Aldrich) was used to evaluate in situ formation of
ROS by a method described by Dal-Ros et al. [33].
Unfixed liver, pancreas and mesenteric artery tissues were
***
**
**
**
** ***
Figure 1 Body weight of ND (■) or HFD (▲) rats over 2 months. The data are expressed as the mean ± SEM with several animals per group
(ND, n = 6 and HFD, n = 10). *: significant difference between the body weight of ND and HFD rats (**: p < 0.01 and ***: p < 0.001).
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(2.5 μM), and incubated in a light-protected humidified
chamber at 37°C for 30 min. The level of ROS was de-
termined using a microscope, and whole tissue fluores-
cence was quantified with NIS-Elements BR (Nikon).
The fluorescence intensity of tissues was quantified in
five arbitrarily selected fields, and the mean value for
each section was calculated. The results were expressed
by comparing the fluorescence between the control ND
and HFD groups.A B
DC
Figure 2 Effect of 2 months of ND or HFD on glucose metabolism of
conditions, glucose tolerance test (IpGTT) (C), and IpGTT area under the cu
n = 10). *: p < 0.05: significant difference between fasting and refeeding c
##: p < 0.01: significant difference between ND and HFD C-peptidemia un
ND and HFD C-peptidemia under refeeding conditions.Statistical analysis
Statistical analysis was performed using STATISTICA®
version 10, Statsoft. Differences between the two groups
(ND, HFD) were evaluated with t-tests after validating
normality. The data are reported as the mean ± SEM for
all parameters except for the islet surface distribution,
where the data were reported as median (interquartile
range). Statistically significant influences of diet are de-
noted by (*). P values <0.05 were considered statistically
significant.rats. Glyceamia (A) and c-peptidemia (B) under fasting and refeeding
rve (D) The data are expressed as the mean ± SEM (ND: n = 6 and HFD:
onditions for glycemia or C-peptidemia between ND and HFD rats.
der fasting conditions. $$$ p < 0.001: significant difference between
Table 2 Effect of ND or HFD on plasma parameters after
2 months
ND HFD
Lipid peroxides TBARS
(μmol/L/mg of total proteins)
2.04 ± 0.29 3.07 ± 0.60
Carbonylated proteins
(nmol/mg of total proteins)
0.25 ± 0.03 0.32 ± 0.03
Triglycerides (mmol/L) 1.58 ± 0.07 8.46 ± 1.19**
Cholesterol (mmol/L) 2.92 ± 0.41 3.43 ± 0.47
HOMA2 2,4 ± 0,12 4,5 ± 0,4***
The data are expressed as the mean ± SEM (ND, n = 6 and HFD, n = 10.
**: p < 0.01; *** p < 0.001: significant differences between ND and HFD rats).
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Effect of HFD on body weight and the metabolic
response
HFD induced a significant increase in body weight
(Figure 1) compared to ND rats (p < 0.01) after only
1 month on this diet. This difference increased after
2 months (HFD: 536.8 ± 11.9 g; ND: 459.3 ± 8.1 g; p <
0.001). After 2 months, fasting glycemia (Figure 2A)
was comparable between ND and HFD rats. Moreover,
30 minutes after refeeding, glycemia was significantlyA
C
Figure 3 Effect of ND (A) or HFD (B) on rat pancreatic islets after 2 m
area was determined (C). *: significant difference in islet surface area betweincreased (p < 0.05) compared to fasting conditions but
comparable between the ND and HFD groups. How-
ever, HFD induced a significant increase in C-peptide
levels after fasting (p < 0.01) or 30 minutes after re-
feeding (p < 0.001). In fact, the HOMA2 was signifi-
cantly increased in HFD rats compared to ND (p <
0.001). HOMA2 of the HFD group was higher than 2.4
confirming insulin resistance (Table 2). Finally, glucose
tolerance testing showed that.
HFD increased glucose intolerance of rats (Figure 2C)
(AUC IpGTT: 224.41 ± 12.01 vs. 148.41 ± 10.84 mg/dL
per minute, p < 0.01, Figure 2D).
The levels of lipid peroxidation and protein carbonyl-
ation were unchanged between the ND and HFD
groups after 2 months. The same results were obtained
for cholesterol. However, HFD induced a significant in-
crease in triglyceride levels (8.46 ± 1.19 mmol/L vs.
1.58 ± 0.07 mmol/L, p < 0.01) (Table 2).
Effect of the HFD on the pancreas and islets
Histological analysis of the pancreas demonstrated a
preservation of the pancreas structure without any fibro-
sis. Indeed, islets were ovoid in form, with cytoplasmsB
onths. Islets were stained with Masson’s trichrome, and the surface
en ND and HFD rats (*: p < 0.05).
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ple (Figure 3A and 3B). Moreover, significant staining of
islets with insulin was observed, reflecting functional is-
lets (data not shown). However, islets from HFD rats
were bigger than those from ND rats, and some holes
were observed in pancreatic tissue that were not ob-
served in ND rats. HDF induced a significant increase in
islet surface are (p < 0.05), (Figure 3C).
Effect of HFD on liver structure and glycogen content
Histological analysis of hepatic tissue from ND rats
showed that the cytoplasm of hepatocytes were homo-
geneously coloured red, the nuclei were well-defined by
violet staining, and cells were organised radially around
centro-lobular veins without fibrosis, resulting in a
steatosis score of 0, according to Kleiner et al. [32]
(Figure 4A). However, widespread steatosis was ob-
served in tissues from HFD rats. Indeed, hepatocytes
were ballooned and contained many vacuoles with
droplets (Figure 4B). Nuclei were less visible and were
at the edge of the cytoplasm, suggesting a level of steatosis
greater than 70% (steatosis score = 3; Kleiner et al. [34]).
Moreover, HFD also induced a significant increase inA
C
Figure 4 Effect of ND or HFD on the rat liver after 2 months. Tissues w
extracted from the liver and quantified (C). The data are expressed as the m
hepatic glycogen between the ND and HFD groups (*: p < 0.05).hepatic glycogen content in the liver compared to ND rats
(p < 0.05) (Figure 4C).
Effect of HFD on ROS production in the pancreas, liver
and mesenteric artery
HFD induced a significant increase in ROS production
in the pancreas, liver and the mesenteric artery after two
months compared to the ND (Figure 5). The level of oxi-
dative stress was increased to 238.2 ± 28.6% (p < 0.01) in
the pancreas, 168.2 ± 17.3% (p < 0.05) in the liver and
147.9 ± 11.6% (p < 0.05) in the mesenteric artery.
Discussion
In this study, we developed a rapidly and easily induced
model of MS by feeding healthy Wistar rats with a HFD.
After only 2 months, this special diet containing seven
fold more fat (21%) and almost the same level of carbo-
hydrates (50%) as the common diet (3% and 60%, re-
spectively), provoked an obesogenic environment which
in turn caused several metabolic disorders: obesity, in-
sulin resistance, hypertriglyceridemia and widespread
alterations in the tissues studied here, including hyper-
plasia of pancreatic islets and hepatic steatosis. TheseB
ere stained with Masson’s trichrome (A and B), and glycogen was
ean ± SEM with five animals per group. *: significant difference in
Figure 5 Effects of ND or HFD on oxidative stress in the pancreas (A), liver (B) and mesenteric artery (C) after 2 months. Tissues from
ND (left pictures) or HFD (right pictures) were stained with DHE, and the amount of DHE was quantified for several animals per group (ND, n = 4-5-4
and HFD, n = 4-4-5, respectively). *: significant difference in oxidative stress between the ND and HFD groups (*: p < 0.05 and **: p < 0.01).
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Moreover, these characteristics were associated with OS
in these tissues and in blood vessels, but not in plasma as
assessed by lipid peroxidation and protein carbonylation.
The metabolic follow-up showed that short-term HFD
induced a significant weight gain in rats after one month,
which was confirmed after 2 months. This weight gain
correlates well to the literature, where many studies report
weight gains in HFD rats treated for different periods
[34-39]. In parallel with this weight gain, HFD rats exhibit
increases in abdominal fat mass (data not shown), indicat-
ing the development of obesity in these rats. This obesity
is accompanied by a significant increase in C-peptide
levels in fasting and re-feeding conditions without changes
in glycemia but associated with an insulin resistance con-
firmed by a significant increase of HOMA2. The same
profiles were reported in Wistar rats fed for 8 weeks with
high-fat, low-carbohydrate diets [39]. Other studies re-
ported both hyperglycemia and hyperinsulinemia after
only 7 weeks of a HFD containing higher fat than in our
study (30-35%) [35]. This suggests that after 8 weeks of
HFD with only 21% fat, we were able to induce hyperinsu-
linism without any change in glycemia. These results also
suggest that to induce hyperglycemia, we should increase
the level of fat in our diet to 35%. Furthermore, a diet rich
in fat (40%) but poor in carbohydrates (14%) was notsufficient to increase glycemia after 2 months [39]. In fact,
short-term MS can be induced by a diet containing at least
20% fat combined with approximately 50% carbohydrates.
In our study, hyperinsulinemia was associated with
hypertriglyceridemia, which was characterised by high
plasma triglyceride levels in HFD rats. The same profile
was also observed by Sasidharan et al. [40] with a diet
containing a comparable fat level. Conversely, the HFD
induced a dramatic increase in hepatic glycogen storage
reflecting the activation of glycogenesis, characteristic of
MS. In contrast, de Castro et al. [41] required more time
(13 weeks) to observe an increase in glycogen deposition
in the liver using a diet with a high level of fat (40%) and a
lower level of carbohydrates (21%). Surprisingly, Gauthier
and colleagues [42] reported a decrease in hepatic glyco-
gen storage in rats fed with a diet with the same level of
carbohydrates (42%) and a higher level of fat (36%) with-
out requiring the same long time period.
Short term HFD also induced important alterations in
pancreatic and hepatic tissues and in blood vessels. In
the pancreas, islet hyperplasia was observed in HFD rats
in response to hyperinsulinism, with observations in-
cluding enlarged cells, holes and an increase in the islet
surface area. The same trend was also reported in mice
fed with a diet with a higher level of fat (60%) for 8, 10
and 12 weeks [43-45] and in rats [46] fed a higher level
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HFD rats exhibit small and widespread vacuoles in the
cytoplasm which are smaller than the nuclei of hepatic
cells. This suggests the presence of microvesicular lipid
deposition characterising hepatic steatosis [32]. This ac-
cumulation of lipids only occurs at hepatic levels. Vacu-
oles were also observed in the livers of rats fed with
HFD with higher levels of fat (58% and 45%) for nearly
the same period of time [34,47].
HFD rats also exhibited an increase in the quantities of
superoxide anions in pancreatic and hepatic tissue and the
mesenteric artery as revealed by dihydroethidium (DHE)
staining compared to rats fed with the ND. This indicates
the development of OS combined with MS, as previously
reported [10-12]. However, OS was only present in tissues,
as we reported no effects of short-term HFD plasma OS
(protein carbonylation and lipid peroxidation). A longer
period of treatment with HFD (more than 2 months) led
to the detection of plasma OS due to increases in the
levels of oxidised proteins and lipids (data not shown).
Some studies reported the appearance of lipid peroxida-
tion in the plasma after 8 weeks [48] or 10 weeks [49] of
HFD containing more fat (32 and 36%) than in our study.
In contrast, few or no studies have reported the analysis of
carbonylated plasma proteins in HFD model rats. Only
Cole and colleagues [50] showed no effect of high-fat
(55%), low-carbohydrate (16%) diets on mitochondrial
proteins after 3 weeks.
The model developed here is essentially linked to the
hypercaloric diet with high fat (21%) and high carbohy-
drate contents (50%), without age-effects. Ghezzi et al.
[3] demonstrated that aging causes the spontaneous de-
velopment of obesity and insulin resistance in adult and
mature rats fed with ND. Other studies have also re-
ported aging-related endothelial dysfunction associated
with oxidative stress [33]. Moreover, most MS models
result in complications that are often irreversible. In
contrast, our model leads to reversible tissue alterations
(data not shown). In fact, we have shown in our laboratory
that the stop of the HFD feeding or the introduction of
antioxidant in the diet could reduce tissue oxidative stress,
restore normal insulin and decrease lipid accumulation in
the liver what makes this model an ideal tool for the de-
velopment of particular diet or the validation of biological
effectiveness of antioxidant compounds.
This study demonstrates that our rapid and simple
model of MS induction by feeding young Wistar rats with
a HFD is a true model of MS as reported in humans. The
model was associated with metabolic disorders, reversible
damage, tissue alterations and OS in the pancreas, liver
and blood vessels, without age-linked effects. This model
presents many advantages, making it a good tool for stud-
ies of MS prevention, including studies assessing new
therapeutic strategies such as antioxidative molecules.Abbreviations
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